Posted in | News | Business | Chemistry | Photonics

Albemarle Completes Construction of New Lab in South Korea

Albemarle (NYSE: ALB), announced today it has completed the R&D laboratory facilities and begun construction on its Yeosu, South Korea manufacturing facility. Albemarle staff, representatives of local construction firm, Safety First, and City of Yeosu officials, including Mayor Kim Chung-seog, joined to mark the occasion.

Mayor Kim thanked Albemarle for its investment in Yeosu and pledged the City's support in this strategic investment. "The rapid development of the site demonstrates Albemarle's commitment to adding immediate value to customers in the region," he commented.

"We are very thankful to the City of Yeosu for its continued strong support of Albemarle as we have escalated construction and engineering design activities for this facility. We look forward to meeting our Asian customers' current needs through local supply in both the metallocene polyolefin industry as well as the High Brightness LED (HBLED) industry," said Jason Bevan, Site Operations Manager - Albemarle Yeosu.

The completion of the Yeosu site R&D lab facility enables the production of metallocene poly-olefin catalyst lab samples incorporating Albemarle's breakthrough ActivCat™ technology for qualification trials with local customers. Pilot plant facilities will be completed in 2010.  Intermediate commercial operations will begin in mid-2011, with the commercial facility being fully operational in 2012. The site will produce finished catalysts, activators like methylaluminoxane (MAO) and metallocene components, as well as High Purity Metal Organics for the HBLED market.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.